We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Offers to Acquire Drug Discovery Platform
Read MoreHide Full Article
Amgen Inc. (AMGN - Free Report) announced that it has offered to acquire Denmark-based drug discovery platform biotech company, Nuevolution, at $3.36 per share (32.5 Swedisk Krona) in cash. Amgen’s offer represents a premium of 169% over the closing price of Nuevolution shares on May 21, valuing it at approximately $167 million (1610 Swedisk Krona). The shares of Nuevolution are listed on the Nasdaq Stockholm Small Cap exchange.
The board of Nuevolution unanimously recommended an acceptance of the offer and three top shareholders, representing 59% shareholdings, have also undertaken to accept the offer. Per the press release, Amgen will provide the offer document on Jun 12. The acceptance period for the offer will commence from Jun 13 and is expected to end on Jul 4. Amgen expects to settle the offer by Jul 15. Amgen will offer cash and restricted stock compensation arrangements to retain the full-time employees of Nuevolution.
Amgen’s shares have declined 12% so far this year against the industry’s rise of 2.2%.
Nuevolution is a leading drug discovery biotech company with its proprietary discovery platform and programs to discover novel small molecule drug candidates. The company partners with other pharmaceutical companies, granting access to its platform.
Please note that Amgen has collaborated with Nuevolution since October 2016 for discovering drugs targeting multiple indications including two cancer programs. The acquisition will bring the Nuevolution’s drug-discovery platform in-house which may boost Amgen's ability to discover novel small molecules against difficult-to-drug targets and make the process faster and more efficient.
We remind investors that while Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales in the future quarters asits mature products are facing competition. Sales of one of the key drugs, Neulasta are declining following rise in biosimilar competition from several companies including Mylan and Coherus BioSciences (CHRS - Free Report) . Meanwhile, sales of Amgen’s new migraine drug, Aimvoig, remained soft in the first quarter of 2019 which faces stiff competition from Lilly’s (LLY - Free Report) Emgality and Teva’s Ajovy,
The company’s potential acquisition of Nuevolution will help Amgen accelerate discovery of drugs targeting various indications with better chances of success. This may lead to newer products, which can offset loss in sales from mature drugs.
Apart from Nuevolution acquisition, Amgen is rapidly advancing its pipeline and the approval of osteoporosis drug Evenity late last month was a boost. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company. It expects to launch additional biosimilars in 2019.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Amgen (AMGN) Offers to Acquire Drug Discovery Platform
Amgen Inc. (AMGN - Free Report) announced that it has offered to acquire Denmark-based drug discovery platform biotech company, Nuevolution, at $3.36 per share (32.5 Swedisk Krona) in cash. Amgen’s offer represents a premium of 169% over the closing price of Nuevolution shares on May 21, valuing it at approximately $167 million (1610 Swedisk Krona). The shares of Nuevolution are listed on the Nasdaq Stockholm Small Cap exchange.
The board of Nuevolution unanimously recommended an acceptance of the offer and three top shareholders, representing 59% shareholdings, have also undertaken to accept the offer. Per the press release, Amgen will provide the offer document on Jun 12. The acceptance period for the offer will commence from Jun 13 and is expected to end on Jul 4. Amgen expects to settle the offer by Jul 15. Amgen will offer cash and restricted stock compensation arrangements to retain the full-time employees of Nuevolution.
Amgen’s shares have declined 12% so far this year against the industry’s rise of 2.2%.
Nuevolution is a leading drug discovery biotech company with its proprietary discovery platform and programs to discover novel small molecule drug candidates. The company partners with other pharmaceutical companies, granting access to its platform.
Please note that Amgen has collaborated with Nuevolution since October 2016 for discovering drugs targeting multiple indications including two cancer programs. The acquisition will bring the Nuevolution’s drug-discovery platform in-house which may boost Amgen's ability to discover novel small molecules against difficult-to-drug targets and make the process faster and more efficient.
We remind investors that while Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales in the future quarters asits mature products are facing competition. Sales of one of the key drugs, Neulasta are declining following rise in biosimilar competition from several companies including Mylan and Coherus BioSciences (CHRS - Free Report) . Meanwhile, sales of Amgen’s new migraine drug, Aimvoig, remained soft in the first quarter of 2019 which faces stiff competition from Lilly’s (LLY - Free Report) Emgality and Teva’s Ajovy,
The company’s potential acquisition of Nuevolution will help Amgen accelerate discovery of drugs targeting various indications with better chances of success. This may lead to newer products, which can offset loss in sales from mature drugs.
Apart from Nuevolution acquisition, Amgen is rapidly advancing its pipeline and the approval of osteoporosis drug Evenity late last month was a boost. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company. It expects to launch additional biosimilars in 2019.
Amgen Inc. Price
Amgen Inc. price | Amgen Inc. Quote
Zacks Rank
Amgen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>